Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer
المؤلفون المشاركون
Abu Tuq, Nifin A.
Saqr, Hanim A.
Abd al-Latif, Atif
المصدر
Journal of the Egyptian National Cancer Institute
العدد
المجلد 22، العدد 1 (31 مارس/آذار 2010)، ص ص. 79-85، 7ص.
الناشر
جامعة القاهرة المعهد القومي للأورام
تاريخ النشر
2010-03-31
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الموضوعات
الملخص EN
Background : tamoxifen has been the mainstay of breast cancer therapy.
Over time, resistance to tamoxifen may develop.
The aromatase inhibitors have proven to be a powerful drug for use in hormone-sensitive early breast cancer.
The switching strategy was designed to combine the apparent superior efficacy of aromatase inhibitors with tamoxifen favourable effects.
Methods : this study was performed on 120 postmenopausal women with histologically confirmed, hormone receptor-positive, operable invasive breast carcinoma who remained free of disease after 2 years of adjuvant tamoxifen therapy.
They were randomized to receive either letrozole 2.5 mg / day (60 patients) or to continue 20mg /day tamoxifen for 5 years (60 patients).
Results : the treatment groups were well balanced in terms of age, tumor size, nodal status, estrogen and progesterone receptor status, and previous surgery.
The disease recurred in 10 patients in the group receiving tamoxifen and 3 patients in the same group switched to letrozole.
There were 8 deaths in the group receiving tamoxifen and 3 deaths in the group of patients who switched to letrozole.
Disease-free survival was higher in the group of patients who switched to letrozole compared to the group of patients who received tamoxifen (p = 0.04), while the overall survival was not statistically significantly different in the two groups.
Letrozole was associated with a significantly lower rate of vaginal bleeding and thromboembolic events.
However, bone fractures and adverse cardiovascular events were more frequent in the arm receiving letrozole than in the arm receiving tamoxifen but these differences were not statistically significant.
Conclusion : switching to letrozole after 2 years of tamoxifen may be better than continuing five years of tamoxifen therapy as regard efficacy and tolerability.
Further study is recommended on a larger group of patients to verify this finding.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Abu Tuq, Nifin A.& Saqr, Hanim A.& Abd al-Latif, Atif. 2010. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. Journal of the Egyptian National Cancer Institute،Vol. 22, no. 1, pp.79-85.
https://search.emarefa.net/detail/BIM-273875
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Abu Tuq, Nifin A.…[et al.]. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. Journal of the Egyptian National Cancer Institute Vol. 22, no. 1 (Mar. 2010), pp.79-85.
https://search.emarefa.net/detail/BIM-273875
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Abu Tuq, Nifin A.& Saqr, Hanim A.& Abd al-Latif, Atif. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. Journal of the Egyptian National Cancer Institute. 2010. Vol. 22, no. 1, pp.79-85.
https://search.emarefa.net/detail/BIM-273875
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 84-85
رقم السجل
BIM-273875
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر